AAD 2026Abstract 73485
Robust icotrokinra systemic and skin pharmacodynamic effects versus deucravacitinib in patients with moderate-to-severe plaque psoriasis
results from phase 3, ICONIC-ADVANCE-1 study
Warren RB, Pieter J Van den Heuvel A, Li H, Chen E, Angsana J, Polak ME, Yum N, DeKlotz C, Sabins N, Gold LS, Gonzalez-Cantero A
AAD Annual Meeting 2026Denver, 27–31 Mar 2026 · published in JAAD 6 Jul 2026
Topics: PsoriasisJAK inhibitors & other targeted pills
Abstract
The abstract’s text is on the JAAD website.
DOI 10.1016/j.jaad.2026.04.1566 · Not in PubMed: details from Crossref